Menu utilisateur

Accès à distance ? S'identifier sur le proxy UCLouvain

Comparability of Prostate Trials

Onglets principaux

Suciu, Stefan [UCL] Sylvester, Richard J. [UCL] Iversen, P. Christensen, I. Denis, L.

The present overview of advanced prostate cancer required the identification of randomized clinical trials studying the question of maximal androgen blockade versus the classic castration therapy. The heterogeneity of the trials concerned the type of castration (surgical or chemical) and the type of antiandrogen (flutamide, Anandron, or cyproterone acetate) added to castration. This paper reviews the different types of heterogeneity that might exist among trials that are involved in the overview: study design, randomization procedure, treatment evaluation, statistical evaluation, and data maturity. In order to overcome these various types of heterogeneity and to compare like with like, the treatment comparison should be stratified a posteriori by question (i.e., type of castration or type of anti-androgen studied) and by study. In this way, one may draw valid conclusions. Of course, those trials with a larger number of patients and a longer follow-up will contribute more to the overview's results.

Type de document Communication à un colloque (Conference Paper) – Présentation orale avec comité de sélection
Année de publication 1993
Langue Anglais
Conférence "3rd International Workshop on Randomized Trials on Maximal Androgen Blockade in M1 Prostate Cancer Patients", PARIS(France) (Jun 19, 1992)
Information sur le périodique "Cancer" - Vol. 72, no. 12, p. 3841-3846 (1993)
Peer reviewed oui
issn 0008-543X
e-issn 1097-0142
Editeur Wiley-liss (New York)
Affiliations UCL - Autre
Liens
  1. Labrie, Clin Invest Med, 5, 267 (1982)
  2. American Cancer Society, Cancer, 66 (1990)
  3. Freedman, Stat Med, 1, 121 (1982)
  4. Pocock, Biometrics, 35, 183 (1979)
  5. . Randomization and stratification in cancer clinical trials: an international survey. In: , , editors. Cancer clinical trials: methods and practice. Oxford: Oxford University Press, 1984: 276–86.
  6. Smith, Cancer, 66, 1009 (1990)
  7. Suciu, Cancer, 66, 1029 (1990)
  8. Dalesio, Cancer, 66, 1080 (1990)
  9. Peto R, Pike M C, Armitage P, Breslow N E, Cox D R, Howard S V, Mantel N, McPherson K, Peto J, Smith P G, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples, 10.1038/bjc.1977.1
  10. The calculation and interpretation of survival curves. In: , , editors. Cancer clinical trials: methods and practice. Oxford: Oxford University Press, 1984: 361–80.
  11. . Analysis of prognostic factors for prostate cancer in the VACURG studies. In: , , , editors. Controlled clinical trials in urologic oncology. New-York: Raven Press, 1984: 147–69.
  12. , . Prognostic factors for randomization and stratification and end points for the evaluation of trials. In: editor. Progress and Controversies in Oncological Urology II. New York: Alan R. Liss, 1988: 275–87. EORTC Genitourinary Group monograph 5.
  13. de Voogt, J Urol, 141, 883 (1989)
  14. Soloway, Cancer, 66, 1017 (1990)
  15. Crawford, Cancer, 66, 1039 (1990)
  16. Gail, Biometrika, 71, 431 (1984)
  17. Early Breast Trialists' Collaborative Group (EBCTCG). Treatment of early breast cancer. Worldwide evidence 1985–1990: a systematic overview of all available randomized trials of adjuvant endocrine and cytotoxic therapy. Oxford: Oxford University Press, 1990.
  18. Keuppens, Cancer, 66, 1045 (1990)
  19. Iversen, Cancer, 66, 1058 (1990)
Référence bibliographique Suciu, Stefan ; Sylvester, Richard J. ; Iversen, P. ; Christensen, I. ; Denis, L.. Comparability of Prostate Trials.3rd International Workshop on Randomized Trials on Maximal Androgen Blockade in M1 Prostate Cancer Patients (PARIS(France), Jun 19, 1992). In: Cancer, Vol. 72, no. 12, p. 3841-3846 (1993)
Permalien http://hdl.handle.net/2078.1/63368